Risk-adapted therapy of multiple myeloma: report from 2012 American Society of Clinical Oncology annual meeting
10.3760/cma.j.issn.1009-9921.2012.07.002
- VernacularTitle:新诊断多发性骨髓瘤的危险分层治疗:来自2012年美国临床肿瘤学会年会的报道
- Author:
Chuanying GENG
;
Wenming CHEN
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Risk-stratification;
Treatment
- From:
Journal of Leukemia & Lymphoma
2012;21(7):390-392
- CountryChina
- Language:Chinese
-
Abstract:
The 48th annual meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago from June 1-5 2012 and the risk-adapted therapy of multiple myeloma (MM) was discussed.MM is a heterogeneous disease and all patients should be accepted risk-adapted therapy. According to cytogenetic abnormalities, MM patients are divided into three groups,standard risk, intermediate risk and high risk.Patients with standard risk may received 4 cycles Rd regimes (lenalidomide plus low dose dexamethasone) or VCD regimes (bortezomib,cyclophosphamide,dexamethasone) for induction therap.Patients with intermediate risk may received 4 cycles VCD regimes for induction therapy.Patients with high risk may received 4 cycles VRD regimes (bortezomib,lenalidomide,dexamethasone) for induction therapy.After induction treatment,patients can received autologous hematopoietic cell transplantation or consolidation/maintenance therapy. The determination of which patients are eligible for autologous hematopoietic cell transplantation according age,comorbidities and performance status.
